Solid Biosciences Inc. (SLDB)
NasdaqGS: SLDB
· 即時價格 · USD
10.25
-0.17 (-1.63%)
收盤價： Sep 04, 2026, 3:59 PM
10.25
+0.00%
盤後: 7:30 PM
股價、關鍵數字和最新消息，都在這一頁。
Solid Biosciences Inc.（SLDB）股價、分析與資料
-1.63% (1D)
| 買價 | 7.46 |
| 市值 | 1.1B |
| 營收 (ttm) | n/a |
| 淨利（ttm） | -207M |
| 2.44 | |
| -1.89 | |
| n/a | |
| -5.87 | |
| P/B (ttm) | 2.88 |
| P/S (ttm) | 0.00 |
| 財報日期 | Nov 2, 2026 |
| 賣價 | 13.08 |
| 成交量 | 495,296 |
| 20 日平均成交量 | 1,584,685 |
| 開盤價 | 10.20 |
| 前收盤價 | 10.42 |
| 當日區間 | 10.20 - 10.48 |
| 52 週範圍 | 3.79 - 11.45 |
| 分析師 | 強<br>購買 |
| 目標價 | 18.5 (80.49%) |
| 股利 | n/a |
| 除息日 | n/a |
關於 SLDB
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the trea...
完整的公司簡介財報驚奇
Solid Biosciences 已於 Aug 6, 2026 公布季度財報：
- 營收為 $0 低於預期 $0, 年增 NaN% 成長.
- 每股盈餘為 -0.38 超出預期 0.09, 年增 35.59% 成長.
第 1 頁，共 2 頁